Supernus Pharmaceuticals Goodwill

Supernus Pharmaceuticals (0LB2.L) currently reports a goodwill of $120M as of June 2026. That compares with $120M in the prior-year period — up 2.1% year over year. Use the charts on this page to explore Supernus Pharmaceuticals's goodwill history and peer comparisons.

Supernus Pharmaceuticals's goodwill increased from $120M to $120M — a 2.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Supernus Pharmaceuticals reported $120M in goodwill as of June 2026. That compares with $120M in the prior-year period — up 2.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current goodwill of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Supernus Pharmaceuticals, and consider following 0LB2.L for alerts when major investors trade the stock.

Supernus Pharmaceuticals is classified in the Healthcare sector. On goodwill, it currently shows $120M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 0LB2.L with unrelated industries.